四川港通医疗设备集团股份有限公司 简式权益变动报告书 签署日期： 2025 年9 月24日 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"） 《上市公司收购管理办法》（以下简称"《收购办法》"）《公开发行证券的公司信息披 露内容与格式准则第15 号——权益变动报告书》等相关法律、法规、规范性文件的规 定编写本报告书。 二、信息披露义务人签署本报告已获得必要的授权和批准。 三、依据《证券法》和《收购办法》的规定，本报告书已全面披露信息披露义务 人在四川港通医疗设备集团股份有限公司（以下简称"港通医疗"）拥有权益的股 份变动情况。截至本报告书签署之日，除本报告书披露的信息外，上述信息披露义务 人没有通过任何其他方式增加或减少其在港通医疗中拥有权益的股份。 四、本次权益变动是根据本报告书所载明的资料进行的。除信息披露义务人之外， 没有委托或者授权任何其他人提供未在本报告书中列载的信息和对本报告书作出任何解 释或者说明。 五、信息披露义务人承诺本报告书不存在虚假记载、误导性陈述或重大遗漏，并对其 真实性、准确性、完整性承担个别和连带的法律责任。 2 上市公司名称：四川港通医 ...

四川港通医疗设备集团股份有限公司 简式权益变动报告书 上市公司的名称：四川港通医疗设备集团股份有限公司 股票上市地点：深圳证券交易所 股票简称：港通医疗 股票代码：301515 信息披露义务人的名称：Ever Thrive Global Limited 住所/通讯地址：Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola, VG1110, British Virgin Islands 股份变动性质：间接持有股份增加 签署日期：2025 年 9 月 24 日 1 四、本次权益变动是根据本报告书所载明的资料进行的。除信息披露义务人 外，没有委托或者授权任何其他人提供未在本报告书中列载的信息和对本报告书 做出任何解释或者说明。 五、信息披露义务人承诺本报告不存在虚假记载、误导性陈述或重大遗漏， 并对其真实性、准确性和完整性承担个别和连带的法律责任。 2 | | | 信息披露义务人声明 一、信息披露义务人根据《中华人民共和国证券法》（以下简称"《证券法》"） 《上市公司收购管理办法》（以下简称"《收购办法》"）《公开发行证券的公司信 ...

Core Viewpoint - The company, 港通医疗, is experiencing a decline in stock performance and has reported significant decreases in revenue and net profit for the first half of 2023, indicating potential challenges ahead [8]. Company Overview - 港通医疗, established on January 13, 1998, is located in Chengdu, Sichuan Province, and was listed on July 25, 2023. The company specializes in providing medical gas systems and clean operating room solutions for medical institutions [7]. - The company's main business revenue composition includes: 55.69% from clean medical equipment and systems, 37.30% from medical gas equipment and systems, 4.06% from medical device sales, 2.81% from operation and maintenance services, and 0.14% from other sources [8]. Financial Performance - For the first half of 2023, 港通医疗 reported revenue of 265 million yuan, a year-on-year decrease of 39.29%, and a net profit attributable to shareholders of -8.4044 million yuan, a year-on-year decrease of 154.53% [8]. - The company has cumulatively distributed 48.9973 million yuan in dividends since its A-share listing [9]. Market Activity - On September 23, 港通医疗's stock fell by 1.99%, with a trading volume of 35.9516 million yuan and a turnover rate of 2.80%, resulting in a total market capitalization of 2.073 billion yuan [1]. - The stock has seen a net outflow of 270,100 yuan from major investors today, with a continuous reduction in major funds over the past three days [4][5]. Strategic Developments - 港通医疗 has developed the 港通云监测平台, which utilizes advanced IoT technology for real-time monitoring of medical equipment in hospitals [3]. - The company plans to repurchase shares with a total fund of no less than 50 million yuan and no more than 100 million yuan, with a maximum price of 28.49 yuan per share, funded by its own resources and a special loan from Bank of China [3]. Industry Position - 港通医疗 has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title for small and medium-sized enterprises in China, indicating its strong market position and innovation capabilities [3].

Market Overview - The Shanghai Composite Index closed at 3781.61 points, with a decline of 1.23% [1] - The total trading volume of A-shares reached 1713.539 billion yuan [1] Technical Analysis - A total of 228 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Innovation Medical: 5-day MA at 22.55 yuan, 10-day MA at 23.23 yuan, a difference of -2.92% [1] - North Long Dragon: 5-day MA at 121.67 yuan, 10-day MA at 123.65 yuan, a difference of -1.60% [1] - Xiangyu Medical: 5-day MA at 54.49 yuan, 10-day MA at 55.34 yuan, a difference of -1.53% [1] Individual Stock Performance - Significant declines in stock prices include: - Innovation Medical: down 4.27% with a turnover rate of 14.36% [1] - North Long Dragon: down 4.52% with a turnover rate of 13.85% [1] - Xiangyu Medical: down 5.86% with a turnover rate of 1.42% [1] - Other notable declines: - Shandong Mining Machine: down 4.43% [1] - Huakang Clean: down 6.50% [1] - Beautiful Ecology: down 5.15% [1] Additional Stock Data - The following stocks also showed significant declines: - Yuyin Co.: down 5.46% [2] - Kexin Information: down 5.22% [1] - Visual China: down 3.88% [1] - Stocks with notable trading activity include: - Hengbao: down 6.64% with a turnover rate of 10.88% [2] - Changbai Mountain: down 6.53% with a turnover rate of 4.05% [2]

Core Viewpoint - The company, 港通医疗, is experiencing fluctuations in stock performance and has recently announced a share buyback plan while also highlighting its achievements in the medical device sector [1][3]. Company Overview - 港通医疗, established on January 13, 1998, is located in Chengdu, Sichuan Province, and specializes in providing medical gas systems and clean operating room solutions for healthcare institutions [7]. - The company's main business revenue composition includes: 55.69% from medical clean equipment and systems, 37.30% from medical gas equipment and systems, 4.06% from medical device sales, 2.81% from operation and maintenance services, and 0.14% from other sources [8]. Financial Performance - For the first half of 2023, 港通医疗 reported revenue of 265 million yuan, a year-on-year decrease of 39.29%, and a net profit attributable to shareholders of -8.4044 million yuan, a year-on-year decrease of 154.53% [8]. - The company has distributed a total of 48.9973 million yuan in dividends since its A-share listing [9]. Recent Developments - 港通医疗 has developed the 港通云监测平台, which utilizes advanced IoT and cloud monitoring technologies to provide real-time monitoring solutions for medical equipment [3]. - The company plans to repurchase shares with a total fund of no less than 50 million yuan and no more than 100 million yuan, with a maximum price of 28.49 yuan per share, funded by its own resources and a special loan from Bank of China [3]. Market Position - 港通医疗 has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, indicating its strong market position and innovation capabilities [3]. - The company is part of the medical device industry, specifically in the medical equipment sector, and is categorized under various concepts including micro-cap stocks and specialized small enterprises [8]. Trading Activity - On September 22, 港通医疗's stock fell by 1.03%, with a trading volume of 17.2185 million yuan and a turnover rate of 1.29%, resulting in a total market capitalization of 2.115 billion yuan [1]. - The stock has seen a net outflow of 198,700 yuan from major investors, indicating a trend of reduced holdings over the past three days [4][5].

Core Viewpoint - As of September 18, 2025, the stock price of Kangtong Medical (301515) closed at 21.7 yuan, reflecting a decline of 2.3% with a trading volume of 17,300 hands and a transaction amount of 37.91 million yuan [1] Group 1: Financial Performance - Kangtong Medical reported a main business revenue of 265 million yuan for the first half of 2025, a year-on-year decrease of 39.29% [3] - The net profit attributable to shareholders was -8.4044 million yuan, a year-on-year decline of 154.53% [3] - The second quarter of 2025 saw a single-quarter main business revenue of 241 million yuan, down 33.22% year-on-year [3] - The company’s gross profit margin stood at 22.09%, significantly lower than the industry average of 51.85% [3] Group 2: Market Activity - On September 18, 2025, the net outflow of main funds was 3.1474 million yuan, accounting for 8.3% of the total transaction amount [1][2] - Retail investors experienced a net outflow of 339,900 yuan, representing 0.9% of the total transaction amount [1][2] - Over the past five days, the stock has seen fluctuations in fund flows, with notable net inflows from speculative funds on several days [2] Group 3: Company Metrics and Industry Comparison - Kangtong Medical's total market value is 2.17 billion yuan, significantly lower than the industry average of 12.073 billion yuan [3] - The company has a price-to-earnings ratio of -129.1, indicating negative earnings performance compared to the industry average of 67.82 [3] - The return on equity (ROE) for Kangtong Medical is -0.67%, while the industry average is 1.8% [3]

Core Viewpoint - The company, Sichuan Portong Medical Equipment Group Co., Ltd., is engaged in the medical device industry, focusing on providing medical gas systems and clean operating room solutions for healthcare institutions. The company has recently faced a decline in revenue and net profit, indicating potential challenges ahead [9]. Company Overview - Sichuan Portong Medical Equipment Group was established on January 13, 1998, and went public on July 25, 2023. The company is headquartered in Chengdu, Sichuan Province [8]. - The main business segments include medical clean equipment and systems (55.69%), medical gas equipment and systems (37.30%), sales of medical devices and other products (4.06%), operation and maintenance services (2.81%), and other supplementary services (0.14%) [9]. Regulatory and Certification - The company has obtained various licenses and certifications, including production licenses for Class I and II medical devices and operating licenses for Class III and II medical devices, allowing it to manufacture and sell a range of medical equipment [2][3]. Financial Performance - For the first half of 2023, the company reported a revenue of 265 million yuan, a year-on-year decrease of 39.29%, and a net profit attributable to shareholders of -8.4044 million yuan, a decline of 154.53% [9]. - The company announced a share buyback plan with a total amount not less than 50 million yuan and not exceeding 100 million yuan, with a maximum price of 28.49 yuan per share [4]. Market Activity - On September 18, the company's stock price fell by 2.30%, with a trading volume of 37.9134 million yuan and a turnover rate of 2.74%, resulting in a total market capitalization of 2.17 billion yuan [1]. - The stock has seen a net outflow of 537,100 yuan from major investors, indicating a reduction in institutional interest [5][6]. Technological Development - The company has developed the Portong Cloud Monitoring Platform, utilizing advanced IoT technology and online cloud monitoring to provide real-time monitoring solutions for medical equipment in hospitals [3]. Industry Recognition - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise by the Ministry of Industry and Information Technology, highlighting its strong innovation capabilities and market position [4].

Core Viewpoint - Equity incentives are becoming a norm in the domestic capital market, serving as an important mechanism for listed companies to improve internal governance [1] Group 1: Overview of Equity Incentives in Sichuan - As of September 17, there are 179 A-share listed companies in Sichuan, with 9 companies implementing equity incentives this year, involving over 1,250 individuals [1] - All 9 companies that have implemented equity incentives are private enterprises, indicating that private companies are the main force behind the promotion of equity incentives in Sichuan [1] - The companies implementing equity incentives span multiple industries, with the defense and military industry being the most concentrated, having 4 companies, followed by the pharmaceutical and biotechnology industry with 2 companies, and the computer, construction decoration, and basic chemical industries with 1 company each [1] Group 2: Specific Companies and Their Incentive Plans - Chengdu XianDao set the grant date for its restricted stock incentive plan as September 15, 2025, granting 1,052,200 shares at a price of 13.99 yuan per share to 102 eligible recipients [1] - Kangtong Medical confirmed the grant date for its restricted stock incentive plan as July 22, 2025, granting 1,230,000 shares at a price of 10.01 yuan per share to 80 eligible recipients [2] - Huatu Shanding determined the initial and reserved grant dates for restricted stocks as July 15, granting a total of 3,049,480 shares at a price of 32.76 yuan per share to 338 individuals [3] - Jiachitech granted 1,187,000 shares of the second category of restricted stocks to 62 eligible recipients on June 3, at a price of 27.86 yuan per share [4] - Junyi Digital set June 20 as the grant date, granting a total of 7,000,000 stock options to 45 eligible recipients at an exercise price of 19.07 yuan per share [5] - Aileda granted 2,814,000 shares of the second category of restricted stocks to 220 eligible recipients on May 16, at a price of 9.25 yuan per share [8] - Zongheng Co. granted 1,735,000 shares of the second category of restricted stocks to 95 eligible recipients on April 17, at a price of 21.68 yuan per share [9] - Qiaoyuan Co. granted 739,700 shares of restricted stocks to 229 eligible recipients on February 27, with a price of 17.64 yuan per share [10]

Group 1 - The core viewpoint of the news highlights the financial performance and trading activity of Kangtong Medical, indicating a significant decrease in revenue and net profit for the first half of 2025 [2] - As of September 11, Kangtong Medical's stock price increased by 0.09%, with a trading volume of 21.90 million yuan and a net financing purchase of 267,100 yuan [1] - The company has a financing balance of 45.03 million yuan, which accounts for 2.97% of its market capitalization, indicating a high level of financing activity compared to the past year [1] Group 2 - Kangtong Medical reported a revenue of 265 million yuan for the first half of 2025, representing a year-on-year decrease of 39.29% [2] - The company incurred a net loss of 8.40 million yuan during the same period, which is a significant decline of 154.53% compared to the previous year [2] - Since its A-share listing, Kangtong Medical has distributed a total of 48.99 million yuan in dividends [3]

Group 1 - The stock of Kangtong Medical increased by 1.53% on September 8, with a trading volume of 38.57 million yuan [1] - On the same day, the financing buy amount was 3.29 million yuan, while the financing repayment was 11.10 million yuan, resulting in a net financing buy of -7.81 million yuan [1] - As of September 8, the total financing and securities lending balance for Kangtong Medical was 42.95 million yuan, accounting for 2.81% of its circulating market value, indicating a high level compared to the past year [1] Group 2 - As of August 29, the number of shareholders for Kangtong Medical was 7,804, a decrease of 10.20% from the previous period [2] - The average circulating shares per person increased by 11.35% to 8,078 shares [2] - For the first half of 2025, Kangtong Medical reported a revenue of 265 million yuan, a year-on-year decrease of 39.29%, and a net profit attributable to the parent company of -8.40 million yuan, a year-on-year decrease of 154.53% [2] Group 3 - Since its A-share listing, Kangtong Medical has distributed a total of 48.99 million yuan in dividends [3]